Antisense Oligonucleotide Therapeutics Market
完整報告名稱與涵蓋範圍
Antisense Oligonucleotide Therapeutics Market Size, Share & Trends Analysis Report, Analysis Report By By ASO Generation (First-Generation, Second-Generation, Third-Generation, Next-Generation), By Phase of Development, By Route of Administration, By Type of Therapy, By Indications, and By Drug Type, By Region, Forecasts, 2025-2034
報告摘要
In 2024, the Antisense Oligonucleotide Therapeutics Market worldwide was assessed at USD 2.2 Billion. Analysts project it will increase to USD 9.1 Billion by 2034, at a CAGR of 15.3% spanning 2025 to 2034.
Antisense Oligonucleotide Therapeutics covers reshaping how healthcare entities approach this space.
The market's upward path is bolstered by surging healthcare spending, technological evolution, and the surging focus on personalized and precision-based approaches in healthcare.
From a segmentation standpoint, the market is categorized across multiple dimensions including product type, application, end-user, and geography, each exhibiting distinct growth patterns and opportunities.
Geographically, North America maintains a leading position owing to advanced infrastructure, high R&D expenditure, and a well-established regulatory environment. Meanwhile, Asia-Pacific is emerging as the fastest-growing region, bolstered by rapid industrialization and expanding end-user bases.
The competitive arena features a mix of established conglomerates and agile innovators, each vying for market position through strategic acquisitions, product launches, and capacity expansion.
The research provides an in-depth evaluation of market forces, competitive positioning, segmental dynamics, and regional trends, equipping stakeholders with actionable intelligence for the forecast period.
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Antisense Oligonucleotides Market Snapshot
Chapter 4. Global Antisense Oligonucleotides Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Opportunities
4.5. Trends
4.6. Investment and Funding Analysis
4.7. Industry Analysis – Porter's Five Forces Analysis
4.8. USFDA Approved Antisense Oligonucleotide Products
4.9. Clinical Trial Analysis
4.10. Key Merger & Acquisitions, Partnership in the Market
4.11. Competitive Landscape & Market Share Analysis
4.12. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Type of Therapy, Estimates & Trend Analysis
5.1. By Type of Therapy, & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Type of Therapy:
5.2.1. Monotherapy
5.2.2. Combination Therapy
5.2.3. Both
Chapter 6. Market Segmentation 2: By Route of Administration Estimates & Trend Analysis
6.1. By Route of Administration & Market Share, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Route of Administration:
6.2.1. Subcutaneous
6.2.2. Intravenous
6.2.3. Intrathecal
6.2.4. Intravitreal
6.2.5. Others
Chapter 7. Market Segmentation 3: By Phase of Development Estimates & Trend Analysis
7.1. By Phase of Development & Market Share, 2024 & 2034
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Phase of Development:
7.2.1. Commercial
7.2.2. Clinical
7.2.3. Preclinical
7.2.4. Discovery Stage
Chapter 8. Market Segmentation 4: By ASO Generation Estimates & Trend Analysis
8.1. By ASO Generation & Market Share, 2024 & 2034
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By ASO Generation:
8.2.1. First-Generation
8.2.2. Second-Generation
8.2.3. Third-Generation
8.2.4. Next-Generation
Chapter 9. Market Segmentation 5: By Drug Type Estimates & Trend Analysis
9.1. By Drug Type & Market Share, 2024 & 2034
9.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Drug Type:
9.2.1. Eleplinsen
9.2.2. Nusinersen
9.2.3. Inotersen
9.2.4. Volanesorsen
9.2.5. Golodirsen
9.2.6. Viltolarsen
9.2.7. Casimersen
9.2.8. Tofersen
9.2.9. Others
Chapter 10. Market Segmentation 6: By Indication Estimates & Trend Analysis
10.1. By Indication & Market Share, 2024 & 2034
10.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Indication:
10.2.1. Duchenne Muscular Dystrophy
10.2.2. Spinal Muscular Atrophy
10.2.3. Transthyretin Amyloidosis
10.2.4. Familial Chylomicronemia Syndrome
10.2.5. Amyotrophic Lateral Sclerosis
10.2.6. Others
Chapter 11. Antisense Oligonucleotides Market Segmentation 7: Regional Estimates & Trend Analysis
11.1. North America
11.1.1. North America Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Type of Therapy, 2021-2034
11.1.2. North America Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Route of Administration, 2021-2034
11.1.3. North America Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Phase of Development, 2021-2034
11.1.4. North America Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By ASO Generation, 2021-2034
11.1.5. North America Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Drug Type, 2021-2034
11.1.6. North America Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Indication, 2021-2034
11.1.7. North America Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts by Country, 2021-2034
11.1.7.1. U.S.
11.1.7.2. Canada
11.2. Europe
11.2.1. Europe Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Type of Therapy, 2021-2034
11.2.2. Europe Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Route of Administration, 2021-2034
11.2.3. Europe Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Phase of Development, 2021-2034
11.2.4. Europe Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By ASO Generation, 2021-2034
11.2.5. Europe Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Drug Type, 2021-2034
11.2.6. Europe Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Indication, 2021-2034
11.2.7. Europe Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts by Country, 2021-2034
11.2.7.1. Germany
11.2.7.2. U.K.
11.2.7.3. France
11.2.7.4. Italy
11.2.7.5. Spain
11.2.7.6. Rest of Europe
11.3. Asia Pacific
11.3.1. Asia Pacific Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Type of Therapy, 2021-2034
11.3.2. Asia Pacific Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Route of Administration, 2021-2034
11.3.3. Asia Pacific Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Phase of Development, 2021-2034
11.3.4. Asia Pacific Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By ASO Generation, 2021-2034
11.3.5. Asia Pacific Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Drug Type, 2021-2034
11.3.6. Asia Pacific Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Indication, 2021-2034
11.3.7. Asia Pacific Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts by Country, 2021-2034
11.3.7.1. Japan
11.3.7.2. China
11.3.7.3. India
11.3.7.4. Australia
11.3.7.5. South Korea
11.3.7.6. Southeast Asia
11.3.7.7. Hong Kong
11.3.7.8. Rest of Asia Pacific
11.4. Latin America
11.4.1. Latin America Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Type of Therapy, 2021-2034
11.4.2. Latin America Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Route of Administration, 2021-2034
11.4.3. Latin America Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Phase of Development, 2021-2034
11.4.4. Latin America Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By ASO Generation, 2021-2034
11.4.5. Latin America Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Drug Type, 2021-2034
11.4.6. Latin America Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Indication, 2021-2034
11.4.7. Latin America Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts by Country, 2021-2034
11.4.7.1. Brazil
11.4.7.2. Mexico
11.4.7.3. Rest of Latin America
11.5. Middle East & Africa
11.5.1. Middle East & Africa Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Type of Therapy, 2021-2034
11.5.2. Middle East & Africa Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Route of Administration, 2021-2034
11.5.3. Middle East & Africa Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Phase of Development, 2021-2034
11.5.4. Middle East & Africa Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By ASO Generation, 2021-2034
11.5.5. Middle East & Africa Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Drug Type, 2021-2034
11.5.6. Middle East & Africa Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts By Indication, 2021-2034
11.5.7. Middle East & Africa Antisense Oligonucleotides Market revenue (US$ Million) estimates and forecasts by Country, 2021-2034
11.5.7.1. GCC Countries
11.5.7.2. South Africa
11.5.7.3. Rest of MEA
Chapter 12. Competitive Landscape
12.1. Major Mergers and Acquisitions/Strategic Alliances
12.2. Company Profiles
12.2.1. Sarepta Therapeutics
12.2.2. Biogen
12.2.3. Alnylam Pharmaceuticals, Inc
12.2.4. Antisense Therapeutics Limited
12.2.5. Sarna Therapeutics GmbH
12.2.6. Arrowhead Pharmaceuticals, Inc.
12.2.7. Atlantic Pharmaceuticals, Inc.
12.2.8. Enzo Pharmaceuticals, Inc.
12.2.9. Bio-Path Holdings, Inc.
12.2.10. Gene Signal International SA
12.2.11. GlaxoSmithKline plc
12.2.12. Gerona Corporation
12.2.13. Gradualist
12.2.14. ICO Therapeutics
12.2.15. Aptos Biosciences
12.2.16. Marina Biotech
12.2.17. mirage Therapeutics, Inc.
12.2.18. Synodic, Inc.
12.2.19. Oncogene Pharmaceuticals Inc.
12.2.20. Pharm axis Ltd
12.2.21. Regulus Therapeutics Inc., Reran Pharmaceuticals, Inc.
12.2.22. RI Pharmaceuticals
12.2.23. Ionis Pharmaceuticals
12.2.24. ProQR Therapeutics
12.2.25. Sterna Biologicals
12.2.26. Wave Life Sciences
12.2.27. Other Prominent Players
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們